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Intraperitoneal (IP) chemotherapy has a proven survival advan-
tage in patients with optimally cytoreduced advanced epithelial ovar-
ian cancer (Armstrong et al., 2006). Placement of IP catheters can be
performed at the time of optimal cytoreductive surgery (Davidson et
al., 1991; Walker et al., 2006). Reported here is the case of a woman
with stage IIIC serous adenocarcinoma of primary peritoneal origin
who underwent optimal cytoreductive surgery and IP catheter place-
ment, who was readmitted on post-operative day 10 with necrotizing
fasciitis of her anterior abdominal wall originating at the IP catheter
site.
Case
A 63-year-old nulligravid female with a pastmedical history signif-
icant for moderately controlled type II diabetes (glycosylated hemo-
globin 7.5%), hypertension, hyperlipidemia, and morbid obesity (BMI
44 kg/m2) presented to her primary care physician with complaints
of twoweeks of lower abdominal pain, bloating, early satiety, and nau-
sea. She was treated with antibiotics for presumed diverticulitis for
2 weeks without resolution of symptoms. A CT scan of the abdomen
and pelvis revealed inﬂammatory changes in the pelvis surrounding
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Open access under CC BY license.present suggestive of uncomplicated diverticulitis, omental nodularity,
and soft tissue prominence in the left adnexa. Pelvic ultrasound
showed a 5 cm calciﬁed ﬁbroid with submucosal extension, and the
ovaries could not be visualized. A serum CA125 level was elevated to
907 U/mL. She was referred to the Gynecologic Oncology clinic for
further evaluation and scheduled for surgery. The patient underwent
a diagnostic laparoscopy, which revealed omental caking, moderate
straw-colored ascites, and bowel adhesions to the anterior abdominal
wall. Due to ﬁndings concerning for malignancy, the procedure was
converted to laparotomy and optimal cytoreduction to b1 cm residual
disease was performed, including total abdominal hysterectomy,
bilateral salpingo-oophorectomy, infragastric omentectomy, appen-
dectomy, resection of proximal descending colon with side-to-side
re-anastomosis. IP port was placed at the time of surgery. Surgical
pathology showed a stage IIIC high-grade serous adenocarcinoma of
primary peritoneal origin.
The immediate post-operative course was uncomplicated and she
was discharged home on post-operative day 5. On post-operative day
10, the patient presented to clinic with complaints of increased left
sided abdominal pain that she described as a constant, pulling sensation
centralized around the IP port site. She also reported brown, watery
discharge from this site. She denied fevers or chills, or other signs of
infection. Evaluation was signiﬁcant for signiﬁcant pain at the port site
without surrounding erythema, and hypotension with blood pressure
79/38 mm Hg, normal pulse of 95 bpm. The patient was taken to the
Emergency Department for further evaluation.
In the Emergency Department, the patient was started on
norephinephrine for blood pressure support and broad-spectrum
antibiotics with piperacillin-tazobactam and vancomycin. CT scan of
the abdomen and pelvis showed massive subcutaneous emphysema
present within the abdominal wall tracking from the IP port site
concerning for necrotizing fasciitis, without evidence of anastomotic
leak or intra-abdominal abscess (Fig. 1). General surgery and inten-
sive care teams were consulted and given the concern for necrotizing
fasciitis and severe sepsis, she was taken to the operating room for
debridement.
Three subcutaneous incisions were made in the left abdominal
wall initially, which did not show evidence of infection or necrotic
tissue. Removal of the IP port then revealed necrotizing fasciitis at
the left upper quadrant IP port reservoir site at the level of the deep
subcutaneous tissue and fascia; superﬁcial tissue showed no evidence
of necrosis. Radical debridement of the abdominal wall, including
anterior fascia, muscle, skin, and soft tissue was performed over a 20 cm
by 10 cm area. A subcutaneous drain was placed, and the wounds were
packed open with betadyne-soaked Kerlix gauze (Fig. 2). On hospital
Fig. 1. Computed tomography image of extensive subcutaneous emphysema surrounding
the IP catheter.
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placed on the 20 cm by 10 cm wound, and the three small wounds
were packed with gauze. Wound cultures grew Enterobacter cloacae,
Streptococcus viridans, and greater than four anaerobic organisms, which
were not speciated by the laboratory. Two sets of blood cultures were
positive for growth of Bacteroides fragilis. Broad spectrum antibiotics
were continued for 7 days, and then narrowed to levoﬂoxacin for the
subsequent 7 days. The patientwasweaned off of pressors after hospital
day 7, and discharged to a transitional care facility on hospital day 11.
The wounds all completely healed within 8 weeks.Fig. 2. Surgical debridement of subcutaneous tissue and anterior fascia surrounding the
IP catheter site was performed.One week after discharge (28 days after her initial cytoreductive
surgery) she presented to clinic with fecal material draining from
the vagina. CT scan showed an anastomotic leak with ﬁstula tract
to the vagina. Review of the CT performed on postoperative day 10
revealed a small pocket of extraluminal air in the presumed ascites
ﬂuid, raising suspicion of a small anastomotic leak, which had not
been identiﬁed on the initial CT read. Due to the patient's poor nutrition
(albumin 1.7 g/dL), surgical management was deferred and a percuta-
neous drain was placed. After 15 weeks, the ﬁstula had completely
resolved, and the drain was removed. She has completed 6 cycles of
primary chemotherapy with IV carboplatin and paclitaxel without
difﬁculty. CA-125 prior to starting chemotherapy (12 weeks after
cytoreductive surgery) had decreased to 123 U/mL, and abdomen
and pelvic CT performed to evaluate the anastamotic leak one week
after initiating chemotherapy showed no radiographic evidence of
disease. CA-125 normalized after the ﬁrst cycle of chemotherapy,
and was 7 U/mL at the completion of chemotherapy.
Discussion
Necrotizing fasciitis is a progressive, polymicrobial, postoperative
infection of the muscular fascia with associated necrosis that was
ﬁrst described by Brewer and Meleney in 1926 (Brewer and Meleny,
1926). Non-necrotizing infections involve the skin (epidermis and
dermis) as well as the subcutaneous tissue and usually respond to
antimicrobial treatment alone. Necrotizing soft tissue infections, how-
ever, involve the skin, subcutaneous tissue aswell asmuscle and fascia,
and require urgent operative debridement.While it is critical to distin-
guish between these two types of soft tissue infections, it is often difﬁ-
cult to discern this difference in the absence of obvious signs of an
underlying necrotizing soft tissue infection.
Patients often present with pain, possibly associated with fever or
cellulitis or crepitus. A thorough history and physical examination are
critical. Risk factors include diabetes, peripheral vascular disease,
immune compromise, and recent surgery. Approximately 5% of cases
occur in the setting of a postoperative infection, in both contaminated
and clean–contaminated operations (Wong et al., 2003). On examina-
tion, pain is often found to be out of proportion to the presenting
symptoms with tenderness beyond the margins of any presenting
erythema or subcutaneous crepitus. Helpful imaging studies in the
absence of overt signs of an infection include a CT scan or an MRI.
The key components of the initial treatment for necrotizing fasciitis
include adequate ﬂuid resuscitation with electrolyte correction, phys-
iologic support of any failing organs, broad-spectrum antimicrobial
treatment, and supportive care. The cornerstone of this treatment
remains urgent and thorough debridement of any necrotic tissue.
Multiple studies have shown that administration of IP chemotherapy
signiﬁcantly improves overall survival, and placement of IP catheters
for IP chemotherapy following optimal cytoreduction of stage III ovarian
cancer has become a standard procedure for many gynecologic oncolo-
gists. The most common catheter complications are port malfunction
(5–9%) and infection (4–10%) (Davidson et al., 1991; Walker et al.,
2006; Landrum et al., 2008; Lesnok et al., 2010; Makhija et al., 2001).
This is the ﬁrst report of necrotizing fasciitis following placement of
an IP catheter at the time of cytoreductive surgery (after PubMed search
of any combination of necrotizing fasciitis, intraperitoneal catheter or
port, ovarian cancer, or cytoreductive surgery). Necrotizing fasciitis is
reported in one case of delayed IP catheter placed under ﬂuoroscopy
by interventional radiology, which was managed by surgical debride-
ment (Rundback et al., 1994).
IP catheter placement at the time of bowel resection is controver-
sial. Authors have suggested avoiding placement of IP catheters at
the time of large bowel surgery (Makhija et al., 2001), however the
data has not proven that this would reduce the rate of catheter com-
plications. Analysis of GOG 172 data suggests that delayed placement
of IP catheters did not decrease the likelihood of complications
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of optimally cytoreduced patients (82% rate of optimal cytoreduction to
b1 cm, ofwhich 22% involved bowel surgery other than appendectomy)
did not reveal a signiﬁcantly increased complication rate when IP
catheters were placed at the time of bowel surgery (14.3% versus 25%
in patients with IP ports placed at the time of bowel surgery versus
patients who did not have IP ports placed, respectively, RR 0.81, 95% CI
0.21, 2.58, n = 14). Rates of bowel surgery did not differ among those
who received and did not receive an IP port at the time of optimal
cytoreductive surgery (p = 0.40). Complications of IP ports placed
at the time of bowel surgery included inﬂow obstruction (n = 1)
and extravasation (n = 1) (Carter et al., 2011).
This case contributes to the body of literature describing complica-
tions of IP catheters. It remains unclear if necrotizing fasciitis in this
case was associated with the large bowel resection or coincidence.
Delayed placement of IP catheters may be considered if large bowel
surgery is performed at the time of cytoreduction, although data is
not deﬁnitive that complication rate will be reduced with delayed
placement. Careful consideration of the risks and beneﬁts of primary
versus delayed placement IP catheters should be performed in cases
of cytoreductive surgery, especially at the time of large bowel resec-
tion with re-anastomosis.Conﬂict of interest statementThe authors declare that there are no conﬂicts of interest.References
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